Logo for Alaunos Therapeutics Inc

Alaunos Therapeutics Investor Relations Material

Latest events

Logo for Alaunos Therapeutics Inc

Q1 2023

Alaunos Therapeutics
Logo for Alaunos Therapeutics

Q4 2023

1 Apr, 2024
Logo for Alaunos Therapeutics

Q3 2023

14 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Alaunos Therapeutics Inc

Access all reports
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company, which develops adoptive TCR engineered T-cell therapies. The company is developing ALNS-1VJ001, a CD19 targeted adoptive cell therapy, to treat B-cell malignancies and lymphomas. Its lead product candidate ALNS-1VJ001 is undergoing clinical trials as a combination therapy with bendamustine hydrochloride (Treanda) for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Alaunos Therapeutics, Inc. has strategic alliance with Merck & Co., Inc.